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Aim: To estimate the clinical and epidemiological pattern of Tuberculosis (TB) in Albania over 
the period 2009-2018. 
Methods: A retrospective analysis of clinical and epidemiological data based on TB individual 
notification forms during the period 2009-2018. 
Results: During the 10-years period, TB incidence increased from 14 to 15.5, but without a sig-
nificant increasing trend. The total number of TB cases increased from 440 to 447. The proportion 
of extra-pulmonary TB decreased from 32% to 25% in 2018 (p=0.015), with and average mean 
change of 29 cases. Males prevail among TB cases and male-to-female ratio ranges from 2:1 to 
3:1. Drug susceptibility testing (DST) was carried out depending on the availability of the reagents 
and there were 54%, 18% and 96% culture cases confirmed positive in 2009, 2014 and 2019, 
respectively. The overall treatment completion rate was 85% and 88.2% in 2009 and 2018, respec-
tively. However, there was a significant drop in cured cases from 26% in 9.3%, whereas the per-
centage of deaths has increased from 0.5% in 4.1%. All treatment outcomes exhibited a significant 
change (p<0.001).  
 
Conclusion: TB continues to be a public health challenge in Albania regardless of the seemingly 
generally stable epidemiological situation. 
 
Keywords: drug resistance, epidemiology, incidence, treatment outcomes, tuberculosis.  
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Introduction 
Tuberculosis (TB) is a communicable disease 
that is a major cause of ill health, one of the 
top 10 causes of death worldwide and the 
leading cause of death from a single infec-
tious agent (ranking above HIV/AIDS). TB 
affects more than 10 million people, causing 
1.6 million deaths worldwide and about a 
quarter of the world’s population is infected 
with M. Tuberculosis (1). 
Geographically, most TB cases in 2018 were 
in the WHO regions of South-East Asia 
(44%), Africa (24%) and the Western Pacific 
(18%), with smaller percentages in the East-
ern Mediterranean (8%), the Americas (3%) 
and Europe (3%) (2).  
Drug-resistant TB continues to be a public 
health threat. In 2018, there were about half a 
million new cases of Rifampicin-resistant 
TB, of which 78% had multidrug-resistant 
TB (MDR) (3).  
Despite the notable progress achieved in the 
fight against TB, countries still face a variety 
of challenges in reaching the goal to end the 
epidemic. Proper and fast diagnosis of TB is 
essential. The sooner a patient is diagnosed, 
the faster their treatment can begin, easing 
suffering and preventing further disease 
transmission. 
Since 1994, the World Health Organization 
(WHO) has developed three main strategies 
for TB prevention and control: directly ob-
served treatment short course (DOTS), Stop 
TB and End TB (4,5). Those strategies fo-
cused on case notification and monitoring of 
treatment outcome as the essential measures 
to evaluate the effectiveness of interventions 
and identify potential gaps in TB control (6). 
The efficacy and successful management of 
any national tuberculosis control program re-
quires reliable clinical and bacteriological di-
agnosis. In order to provide these data, a na-
tional tuberculosis surveillance system was 
implemented based on individual data since 
2008.  
Trend in case notification rate, age group af-
fected by TB, bacteriological resistance, 
treatment outcomes and clinical form are the 
main indicators used to evaluate the National 
TB Program. All these indicators were ana-
lysed in the current study (7-9). The aim of 
the present study was to estimate the clinical 
and epidemiological pattern of TB in Albania 
over the period 2009-2018. 
 
Methods 
The data were obtained from the register at 
the National Tuberculosis Control Program 
(NTBP) at the University Hospital of Lung 
Diseases "Shefqet Ndroqi" (SUSM), Tirana, 
Albania. Data on tuberculosis patients are 
recorded and reported individually and in ac-
cordance with the guidelines of the World 
Health Organization and the European TB 
Supervision Centre (6).  
The data are collected and reported for each 
individual patient in accordance with the no-
tification reporting form designed in 2001. 
The notification form includes detailed data 
on TB and other related factors. The study an-
alyse the data reported, recorded and evalu-
ated at NTBP and included general patient 
data, address, sex, occupation, age, diagnosis, 
direct sputum and culture results, as well as 
anti-tuberculosis drug sensitivity results and 
treatment outcomes. 
Statistical analysis was performed in SPSS 
25.0 (Statistical Package for Social Sci-
ences). Categorical variables were presented 
in absolute numbers and corresponding per-
centages. 
Arithmetic averages were calculated for all 
numerical variables. Differences between 
groups for discrete variables, nonparametric 
data, were performed using the Hi-square 
test. The values of p≤0.05 were considered 
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significant. Population estimates were based 
on 2002 census data, with extrapolation.  
 
Results   
Trends analysis of tuberculosis incidence  
In the study period, the incidence rate of TB 
per 100,000 inhabitants/year went from 13.4 
in 2009 to 14.2 in 2018 (Figure 1); there is no 
evidence of any significant linear trend in the 
incidence rate of tuberculosis in Albania in 
the past decade (P>0.05). 
The mean percentage of annual changes of 
TB notification rate from 2009 to 2018 was 
6.6%. 
 





Tuberculosis cases by site of disease 
The number of reported cases of pulmonary 
TB in Albania varies by about 5.3% on aver-
age each 
year, from 2009 to 2018. As a result, the pro-
portion of total cases with extra pulmonary 
decreased from 32% in 2009 to 25% in 2018 
(p=0.015, difference between 2009 vs 
2018).The average mean change is 29 cases, 
which shows a stable trend. Figure 2 shows 
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Sex and age distribution 
Males predominate among TB cases in all 
study period and male: female ratio ranges 
from 2:1 to 3:1. 
Young adults (15-44) and the middle-aged 
(45-64) together represented 76.5% of all 
cases and respectively 47.4% and 29.1% in 
2009. Young adults and the middle-aged rep-
resented 73% in 2018, but there was a signif-
icant increase in the age group>65 from 
19.7% in 2009 to 26.1% in 2018(p=0.014). 
 















































0-15 18 (4.03) 4 (0.91)  0.002 
15-25 86 (19.24) 81 (18.41) 0.409 
25-35 63 (14.09) 83 (18.86) 0.034 
35-45 62 (13.87) 37 (8.41) 0.006 
45-55 71 (15.88) 58 (13.18) 0.148 
55-65 59 (13.20) 62 (14.09) 0.386 
>65 88 (19.69) 115 (26.14) 0.014 
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There was an increase in the age group 25-34 
from 14.2% to 18.8% and in the age group 
over 65 from 19.4% to 26.1%, while there 
was a decrease in the age group 35-44 
from13.9% to 8.5%. Children accounted re-
spectively for 4.1% and 0.9% in 2009 and 
2018. 
Young adults (15-44) and the middle-aged 
(45-64) together represented 76.5% of all 
cases and respectively 47.4% and 29.1% in 
2009. Young adults and the middle-aged rep-
resented 73% in 2018, but there was a signif-




Bacteriological confirmation and drug sus-
ceptibility testing  
The proportion of bacteriologically con-
firmed cases remained high during the study 
period and there was not great variation an-
nually in smear confirmation cases. Average 
mean change was 17 ± 13 cases per year, 
which shows a constant trend. 
Drug susceptibility testing (DST) was carried 
out in a small proportion of pulmonary TB 
cases, only for 30% of cases in 2018 due to 
shortage of reagent. The number of cultures 
tested dropped from 201 in 2009 to 63 in 
2018, but starting from 2013 the number of 
tests was reduced dramatically, and conse-
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Table 2. Proportion of smear positive cases, MDR and number of drug  
susceptibility testing 
Year  PTB Smear 
positive 





2009 305 192 63% 0 201 
2010 275 165 60% 2 182 
2011 301 190 63% 5 203 
2012 312 206 66% 0 163 
2013 333 212 64% 1 27 
2014 261 175 67% 2 29 
2015 296 209 71% 3 13 
2016 299 206 69% 1 40 
2017 346 210 61% 0 79 
2018 330 208 63% 2 63 
 
Treatment outcomes  
The overall treatment success rate was 85% 
and 88.2% in 2009 and 2018, respectively. 
There is a significant drop in cured cases in 
2009 from 26% to 9.3% in 2018. Also, the 
percentage of deaths increased from 0.5% to 
4.1%. All treatment outcomes displayed a 
significant change (p<0.001).  
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Discussion 
The number of patients diagnosed with tuber-
culosis in the study period had a slight oscil-
lation with an insignificant trend of increase 
in TB incidence. The incidence increased 
from 13.4% in 2008 to 15.3% in 2018. There 
was no evidence of a trend and a statistically 
significant change in the incidence rate over 
the study period. The incidence of TB ap-
pears to be more or less stable, but if we com-
pare it with the neighbouring countries or 
other European countries, we notice that Al-
bania is the only country in the region with 
increased TB incidence and a positive mean 
annual change (Table 3). There is a wide var-
iation in TB incidence in the Balkan region 
from 4 (Greece) to 39 (Kosova) cases per 
100,000 population.  
 
Table 3. TB incidence in the Balkan region 
Country  TB incidence 2009 
(cases per 100,000) 
TB incidence 2018 MACH* 
2014-2018 
Albania 13.4 15.3 2.0% 
Kosova 60 39.2 -4.6% 
Montenegro 19.2 13.4 -7.2% 
North Macedonia 23.2 10.4 -6.6% 
Serbia 17.2 9.4 -7.0% 
Grecee 5.2 4 -4.1% 
 
This indicates that stability of TB incidence 
over the years in Albania is not a good TB 
programme indicator and the National TB 
Programme has to analyse the cause of this 
stagnation. Furthermore, despite the stable 
incidence, the proportion of pulmonary TB 
cases increased to 75% in 2018, posing a se-
rious risk of spreading cases with infectious 
TB and consequently increasing TB inci-
dence in coming years. 
The proportion of extra pulmonary TB con-
tinues to be high despite the significant de-
crease during the last years. The lowest pro-
portion 25% was in 2018 and the higher was 
38% in 2010. There is a stable trend in de-
creasing the proportion of extra pulmonary 
cases, although the proportion remains high 
compared to the region. The proportion of ex-
tra-pulmonary TB was 14% in Greece, 11% 
in Serbia, 12% in Monte Negro, 24% in North 
Macedonia and 29% in Kosovo in 2019. The 
variances in the reporting of extra-pulmonary 
TB may result from different diagnostic prac-
tices across the country in the region or epi-
demiological factors and the prevailing M. 
TB strains (10). 
Males predominate among TB cases in all 
study period and male: female ratio ranges 
from 2:1 to 3:1.  
There were twice as many males as females 
reported among all incident TB cases in Eu-
ropean region, but large variation was ob-
served for male predominance in the sex dis-
tribution of TB cases, ranging from almost an 
even distribution to over three times greater 
in Armenia and Albania. There are few pub-
lications on TB gender differences world-
wide and it is not clear whether the differ-
ences in morbidity between the sexes are due 
to biological factors, socioeconomic context, 
or under diagnosis of TB in women who are 
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likely to have the least access to health care 
(11,12). In Albania, the disease of tuberculo-
sis continues to be an important cause of mor-
bidity in women.  
The differences between the sexes have been 
constantly ascertained, but there is no study 
to assess these changes (13). 
Bacteriological confirmation of TB diagnosis 
was high during the study period, over 60%, 
and there was not great variation annually in 
smear confirmation cases.  
A high proportion of bacteriologically con-
firmed PTB cases might imply a delay in di-
agnosis and may reflect several gaps in diag-
nosis, such as lack of capacity by the program 
to accurately diagnose TB through bacterio-
logical examination (14).  
The proportion of bacteriologically con-
firmed cases among pulmonary TB varied 
considerably among the countries in the re-
gion from 45% in Kosovo to 95% in Serbia. 
The increasing proportion in other countries 
in the region is due to the implementation of 
the new technology in these countries, specif-
ically GeneXpert. Thus, the proportion of 
bacteriologically confirmed cases before and 
after application of GeneXpert in Monte Ne-
gro was 59% and 86% respectively, in Bosnia 
and Herzegovina 42% and 74% and in North 
Macedonia 65% and 90%, respectively. Al-
bania has installed last year two GeneXpert 
and we expect an increase in the bacteriolog-
ical confirmation like in other neighbouring 
countries (15). 
MDR-TB is a major issue in the Balkan re-
gion with the percentage of MDR-TB among 
all TB cases increasing over the last 10 years 
from 4.3% to 7.5% (16). Drug susceptibility 
testing was carried out in a small proportion 
of pulmonary TB cases (only for 30% of the 
cases) and we cannot analyse this important 
indicator, but the proportion of MDR re-
sistance remains low (less than 3% over the 
study period). Albanian government must 
provide the necessary reagent for performing 
drug susceptibility test and evaluating the 
real situation of MDR in Albania.  
Over the study period, the treatment success 
rates continued to improve, but the cure rate 
decreased significantly due to the lack of bac-
teriological confirmation during the follow 
up treatment phase. The number of deaths in-
creased, but there are only few numbers to 
draw a valid statistical conclusion. 
 
Conclusion 
Despite the stagnation of the total number of 
TB cases during the study period, the epide-
miological situation should not be assessed as 
stable, but deteriorating. MDR situation is 
unknown due to the shortage of reagent and 
pose a threat to TB control. The other epide-
miological indicators like treatment out-
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